Cure My Disease

Don't miss your cure!

 Log in / Sign up

South korea tracks Real-World safety of bladder cancer drug PADCEV

NCT ID NCT06011954

Recruiting now Knowledge-focused Sponsor: Astellas Pharma Korea, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This study monitors 202 adults in South Korea with advanced bladder cancer who are receiving the drug PADCEV (enfortumab vedotin) as part of their normal care. Researchers will track side effects and how well the cancer responds for up to a year. No new treatment is given; the goal is to gather real-world safety and effectiveness data.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Enfortumab vedotin (PADCEV)
What this could lead to
If successful, this study will provide real-world safety and effectiveness data on PADCEV for advanced bladder cancer in South Korean patients.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be limited by small sample size and short follow-up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UROTHELIAL CANCER

Contacts and locations

Locations

  • Site KR82001

    RECRUITING

    Goyang-si, Gyeonggi-do, 10408, South Korea

  • Site KR82002

    RECRUITING

    Seoul, 02841, South Korea

  • Site KR82003

    RECRUITING

    Seoul, 03722, South Korea

  • Site KR82004

    ACTIVE_NOT_RECRUITING

    Incheon, 21565, South Korea

  • Site KR82005

    RECRUITING

    Seoul, 03181, South Korea

  • Site KR82006

    RECRUITING

    Seoul, 07417, South Korea

  • Site KR82007

    COMPLETED

    Jeollanam-do, Jeollanam-do, 58128, South Korea

  • Site KR82008

    RECRUITING

    Suwon, Gyeonggi-do, 16500, South Korea

  • Site KR82009

    ACTIVE_NOT_RECRUITING

    Busan, 49201, South Korea

  • Site KR82010

    COMPLETED

    Busan, 48108, South Korea

  • Site KR82011

    RECRUITING

    Seoul, 07985, South Korea

  • Site KR82012

    RECRUITING

    Suwon, Gyeonggi-do, 16247, South Korea

  • Site KR82013

    RECRUITING

    Jeonju, Jeonbuk-do, 54907, South Korea

  • Site KR82014

    RECRUITING

    Daegu, 42415, South Korea

  • Site KR82015

    ACTIVE_NOT_RECRUITING

    Busan, 47392, South Korea

  • Site KR82016

    COMPLETED

    Busan, 50612, South Korea

  • Site KR82017

    ACTIVE_NOT_RECRUITING

    Seoul, 06351, South Korea

  • Site KR82018

    RECRUITING

    Daejeon, 35365, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.